Financials

Company Profile

November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.

Employees

157

Sector

Date	Price	Change	Volume

Delayed Quote OTC Markets

Delayed OTC Markets 19:10:15 15/10/2026 +03			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-99.00%	-

27/08/25	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/05/25	EnVVeno Medical Names Jennifer Bright CFO	MT

27/08/25	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/05/25	EnVVeno Medical Names Jennifer Bright CFO	MT
05/03/25	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/02/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/02/25	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/02/25	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/02/25	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/01/25	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/01/25	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/01/25	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/01/25	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/12/24	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/11/24	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/04/24	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/05/23	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
20/01/23	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
20/05/22	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

14/10/25	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/11/24	Biolase: Q3 Earnings Snapshot	AQ
08/11/24	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
01/10/24	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
08/08/24	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	10/09/2025
Steven Sandor COO	Chief Operating Officer	46	06/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	01/10/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	01/09/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	16/08/2021
Martha Somerman BRD	Director/Board Member	-	16/08/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/28/23 A	Goldman Sachs & Co. LLC (Private Banking)	Other	Company	144,501	13.8444%
6/8/23 A	Jonathan Lord	Free	Chairman	721,154	2.3039%
6/8/23 A	Kathleen O'Loughlin	Free	Director	502,404	1.6050%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE, INC.	-99.00%	-99.00%	-99.50%	-100.00%	36
INVESTOR AB	-1.54%	-0.47%	+30.62%	+104.79%	129B
INDUSTRIVÄRDEN AB	-0.68%	0.00%	+30.43%	+82.86%	22.39B
HAL TRUST	0.00%	+0.98%	+20.88%	+55.09%	16.64B
MERITZ FINANCIAL GROUP INC.	-1.30%	-0.39%	+15.65%	+153.03%	15.83B
LUNDBERG B	-0.53%	-0.53%	+11.54%	+28.09%	14.26B
INVESTMENT AB LATOUR	-1.22%	+0.29%	-12.43%	+10.06%	13.48B
KINGDOM HOLDING COMPANY	-2.98%	-8.18%	+62.48%	+81.29%	12.92B
BAJAJ HOLDINGS & INVESTMENT LIMITED	+1.56%	+4.14%	-11.15%	+63.90%	13.19B
WASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED	-0.63%	+1.26%	+21.11%	+33.27%	12.26B
Average	-10.57%	-0.08%	+6.97%	+51.24%	25.01B
Weighted average by Cap.	-1.10%	-0.26%	+24.58%	+86.22%